Optiray 350

  • Imaging agents

Optiray 350 Generic Name & Formulations

General Description

Ioversol 741mg/mL; soln for intra-arterial or intravenous inj; contains organically bound iodine 350mg per mL.

Pharmacological Class

Radiopaque contrast agent.

How Supplied

OPTIRAY 300: Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 100mL)—20, RFID-Tagged syringes (100mL)—20; OPTIRAY 320: Vials (20mL, 30mL)—25, Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 100mL, 125mL)—20

Generic Availability


Optiray 350 Indications


Adults: Peripheral and coronary arteriography, and left ventriculography. Computed tomography (CT) imaging of the head and body, venography, and intravenous (IV) excretory urography. IV digital subtraction angiography (IV-DSA). Children: Angiocardiography.

Optiray 350 Dosage and Administration


Individualize. Peripheral arteriography (aortic-iliac runoff): 60mL (range 20–90mL); (common iliac, femoral): 40mL (range 10–50mL); (subclavian, brachial): 20mL (15–30mL); all: max 250mL. Coronary arteriography and left ventriculography (left coronary): 8mL (range 2–10mL); (right coronary): 6mL (range 1–10mL); (left ventricle): 40mL (range 30–50mL); all: max 250mL. Venography: 50–100mL per extremity; max 250mL. CT (head): 50–150mL by infusion; (body): may give as 25–75mL bolus inj or 50–150mL by infusion, or combination of both. IV urography (usual dose): 50–75mL; (high dose): 1.4mL/kg; max 140mL. IV-DSA: 30–50mL; may repeat as necessary; max 250mL; (central catheter inj): give at a rate of 10–30mL/sec; (peripheral inj): 12–20mL/sec.


Angiocardiography: 1.25mL/kg (range 1–1.5mL/kg); max 5mL/kg up to max 250mL.

Optiray 350 Contraindications


Symptomatic hyperthyroidism.

Optiray 350 Boxed Warnings

Boxed Warning

Risks with inadvertent intrathecal administration. For intra-arterial and intravenous use only.

Optiray 350 Warnings/Precautions


Inadvertent intrathecal administration; may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. History of previous reactions to a contrast agent and known allergies (eg, bronchial asthma, drug, or food) and other hypersensitivities; monitor. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Monitor for severe cardiovascular reactions. Risk of serious thromboembolic events (eg, MI, stroke) during angiographic procedures. Avoid angiography with homocystinuria. CHF. Dehydration. Diabetes. Advanced vascular disease. Multiple myeloma or other paraproteinemia. Hyperthyroidism. Autonomous thyroid nodule. Thyroid dysfunction (esp. children 0–3yrs); monitor. Pheochromocytoma or catecholamine-secreting paraganglioma: monitor closely. Homozygous sickle cell disease. History of severe cutaneous adverse reactions (SCAR); avoid. Hepatic or renal impairment. Use lowest effective dose. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy. Nursing mothers: consider interrupting, pumping, and discarding breast milk for 8hrs after Optiray.

Optiray 350 Pharmacokinetics

See Literature

Optiray 350 Interactions


Increased risk of metformin-induced lactic acidosis; discontinue metformin at the time of, or prior to, Optiray in high risk patients (see full labeling). May antagonize radioactive iodine for thyroid carcinoma for up to 6–8wks. Defer in patients with hepatic impairment who recently received oral cholecystographic contrast agents. Caution with concomitant diuretics, nephrotoxic agents. Avoid laxatives, diuretics prior to administration. Protein-bound iodine or radioactive iodine uptake study results may not accurately reflect thyroid function for up to 16 days.

Optiray 350 Adverse Reactions

Adverse Reactions

Nausea; hypersensitivity reactions, acute kidney injury, cardiovascular reactions, SCAR (eg, SJS/TEN, DRESS). Also in children: fever.

Optiray 350 Clinical Trials

See Literature

Optiray 350 Note

Not Applicable

Optiray 350 Patient Counseling

See Literature